74 articles for G Zhao
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Synthesis of potent and highly selective inhibitors of human tryptase.
The Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors.
The Bristol-Myers Squibb Pharmaceutical Research Institute
Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.
Genentech
Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.
Genentech
Design and discovery of 5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxamide inhibitors of HIV-1 integrase.
Shandong University
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Genentech
Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Genentech
Discovery of nonbenzamidine factor VIIa inhibitors using a biaryl acid scaffold.
Bristol-Myers Squibb Research & Development
Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.
Forma Therapeutics
Synthesis anda-glucosidase inhibitory activity evaluation of N-substituted aminomethyl-ß-d-glucopyranosides.
Xi'An Jiaotong University
Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.
Genentech
Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
Forma Therapeutics
A new series of N2-substituted-5-(p-toluenesulfonylamino)phthalimide analogues asa-glucosidase inhibitors.
Xi'An Jiaotong University
Substituted piperidinyl glycinyl 2-cyano-4,5-methano pyrrolidines as potent and stable dipeptidyl peptidase IV inhibitors.
Bristol-Myers Squibb Research and Development
Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.
Genentech
Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling.
Genentech
Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:diacylglycerol acyltransferase 1.
Abbott Laboratories
Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.
Genentech
Novel oxadiazole analogues derived from ethacrynic acid: design, synthesis, and structure-activity relationships in inhibiting the activity of glutathione S-transferase P1-1 and cancer cell proliferation.
Shandong University
Discovery and synthesis of novel luteolin derivatives as DAT agonists.
Zhengzhou University
Synthesis and biological evaluation of 4-fluoroproline and 4-fluoropyrrolidine-2-acetic acid derivatives as new GABA uptake inhibitors.
Institute of Microbiology
Novel fatty acid synthase (FAS) inhibitors: design, synthesis, biological evaluation, and molecular docking studies.
Institute of Pharmacology and Toxicology
1-Oxo-3-substitute-isothiochroman-4-carboxylic acid compounds: synthesis and biological activities of FAS inhibition.
Institute of Pharmacology & Toxicology
Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors.
Bristol-Myers Squibb Research and Development
An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53.
Shandong University
Identification of diamino chromone-2-carboxamides as MCHr1 antagonists with minimal hERG channel activity.
Abbott Laboratories
Discovery of novel pyridinones as MGAT2 inhibitors for the treatment of metabolic disorders.
Bristol Myers Squibb
An evaluation of 3,4-methylenedioxy phenyl replacements in the aminopiperidine chromone class of MCHr1 antagonists.
Abbott Laboratories
Constrained 7-fluorocarboxychromone-4-aminopiperidine based Melanin-concentrating hormone receptor 1 antagonists: the effects of chirality on substituted indan-1-ylamines.
Abbott Laboratories
Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safety.
Abbott Laboratories
Design, synthesis and promising anti-tumor efficacy of novel imidazo[1,2-a]pyridine derivatives as potent autotaxin allosteric inhibitors.
Shenyang Pharmaceutical University
Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists.
Abbott Laboratories
Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonists.
Abbott Laboratories
Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
Nantong University
Discovery and SAR of 4-aminopyrrolidine-2-carboxylic acid correctors of CFTR for the treatment of cystic fibrosis.
Abbvie
Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders.
TBA
Synthesis of potent and highly selective nonguanidine azetidinone inhibitors of human tryptase.
The Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis and biological evaluation of selective survivin inhibitors derived from the MX-106 hydroxyquinoline scaffold.
University of Tennessee Health Science Center
Synthesis of potent and selective 2-azepanone inhibitors of human tryptase.
The Bristol-Myers Squibb Pharmaceutical Research Institute
Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling.
Genentech
Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi
Gilead Sciences
Small molecules targeting HIF-1α pathway for cancer therapy in recent years.
Shandong University
Discovery of novel pyrazole derivatives as potential anticancer agents in MCL.
Shandong University
Discovery of ABBV/GLPG-3221, a Potent Corrector of CFTR for the Treatment of Cystic Fibrosis.
Abbvie
Design and synthesis of novel pyrimidone analogues as HIV-1 integrase inhibitors.
Shandong University
Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.
Bristol-Myers Squibb Research and Development
Design and synthesis of novel nitrogen-containing polyhydroxylated aromatics as HIV-1 integrase inhibitors from caffeic acid phenethyl ester.
Shandong University
Amide-containing diketoacids as HIV-1 integrase inhibitors: synthesis, structure-activity relationship analysis, and biological activity.
Shandong University
Triazole-linked transition state analogs as selective inhibitors against V. cholerae sialidase.
University of California-Davis
Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity.
Shandong University
Benzenesulfonylbenazamide compound for inhibiting BCL-2 protein and composition and use thereof
Shenzhen Targetrx
Crystal form of urate transporter 1 inhibitor and preparation method and use thereof
Tianjin Institute of Pharmaceutical Research
Piperazinyl norbenzomorphan compounds and methods for using the same
University Of Texas
Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
Bristol-Myers Squibb
Substituted 3,4,5,6,8,10,14,14a-octahydro-2h-2,6-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazocines and methods for treating viral infections
Gilead Sciences
Synthesis, activity evaluation, and docking analysis of barbituric acid aryl hydrazone derivatives as RSK2 inhibitors.
East China University of Science and Technology
Substituted benzimidazole and imidazopyridine compounds useful as CYP17 modulators
Bristol-Meyers Squibb
Type II Ligands as Chemical Auxiliaries To Favor Enzymatic Transformations by P450 2E1.
Mcgill University
Hydroxyethylene sulfones as a new scaffold to address aspartic proteases: design, synthesis, and structural characterization.
Philipps-Universitat Marburg
Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
University of Auckland